SLC25A11 and glioblastoma: Specifically, two GBM TSs with high SLC25A11 expression, TS13-64 and TS15-88, were treated with various concentrations of KN612 for 72 h, and the protein and mRNA expression of MAS-related factors were examined KN612 treatment significantly downregulated SLC25A11 protein and mRNA expression levels in TS13-64 and TS15-88 compared with those in the control group (Fig. 2b, c; Supplementary fig.